DAE HWA PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,690 KRW | -2.82% |
|
+3.69% | +13.97% |
| Sales 2018 | 110B 79.96M 6.39B | Sales 2019 | 115B 83.21M 6.65B | Capitalization | 223B 162M 12.93B |
|---|---|---|---|---|---|
| Net income 2018 | 6.65B 4.83M 386M | Net income 2019 | 10.54B 7.65M 612M | EV / Sales 2018 | 3.44 x |
| Net Debt 2018 | 28.81B 20.91M 1.67B | Net Debt 2019 | 39.64B 28.78M 2.3B | EV / Sales 2019 | 2.29 x |
| P/E ratio 2018 |
52.7
x | P/E ratio 2019 |
21.3
x | Employees | 308 |
| Yield 2018 |
0.76% | Yield 2019 |
1.17% | Free-Float | 64.95% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.82% | ||
| 1 week | +3.69% | ||
| Current month | +3.99% | ||
| 1 month | +5.22% | ||
| 3 months | +20.52% | ||
| 6 months | +7.65% | ||
| Current year | +13.97% |
1 week
10 650.00
11 740.00
1 month
9 280.0012 360.00
Current year
8 680.0013 670.00
1 year
7 390.0015 980.00
3 years
5 940.0015 980.00
5 years
5 820.0023 000.00
10 years
5 820.0059 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Byung-Tae Noh
CEO | Chief Executive Officer | 62 | 14/12/85 |
Eun-Seok Kim
CEO | Chief Executive Officer | 48 | 31/01/08 |
Jae-Seong Na
DFI | Director of Finance/CFO | 55 | 31/01/93 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eun-Seok Kim
CEO | Chief Executive Officer | 48 | 31/01/08 |
Byung-Tae Noh
CEO | Chief Executive Officer | 62 | 14/12/85 |
Sang-Tae Lee
BRD | Director/Board Member | 59 | 28/02/89 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 10,690 | -2.82% | 259,771 |
| 25/04/24 | 11,000 | -0.99% | 281,359 |
| 24/04/24 | 11,110 | -1.24% | 265,117 |
| 23/04/24 | 11,250 | -2.60% | 572,924 |
| 22/04/24 | 11,550 | +12.03% | 5,058,769 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
DAE HWA PHARM CO.,LTD. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products include skeletal muscle relaxants, gastro-intestinal drugs, corticosteroids, antihistamines, cardiovascular drugs, drugs for liver diseases, vitamins, tonics, antibiotics, injections, topical drugs, anti-inflammatory enzymes, analgesics, antipyretics, plaster, cough suppressants, expectorants and mucolytics, drugs for hemorrhoid disease and other prescription drugs, as well as over-the-counter (OTC) drugs. The Company distributes its products within domestic market and to overseas markets. On August 22, 2013, it acquired a certain shares of a Korea-based company, which is mainly engaged in the manufacture of medicine raw materials and development of medical devices. After the transaction, the Company held a 100% stake of the Korea-based company.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.97% | 136M | |
| +3.99% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- A067080 Stock
